arrow
T

Tiziana Triulzi

department of experimental oncology
H指数:32
被引数:4,569

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness

去细胞化乳腺癌的蛋白质组学景观鉴定C-type lectin domain family 3 member A为癌症侵袭性的驱动因子

2025-06-060
OAAI
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

CD36富集在HER2阳性间充质干细胞中,驱动乳腺癌的治疗抵抗性

2025-01-201
OA
SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness

肿瘤细胞对脂肪细胞的SAA1-dependent重编程与三阴性乳腺癌侵袭性相关

2024-01-305
OA
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
2023-06-017
PRE
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

人 (NCT03447678),一线II期pembrolizumab试验,在阴性和低PD-L1晚期NSCLC中: 临床结果和与循环免疫生物标志物的关联

2022-12-015
OAAI
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
2022-07-0515
OA
The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study
2022-02-150
PRE
High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study
2022-02-151
PRE
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial

TRAR基因分类器预测HER2-positive和ER阳性乳腺癌患者对新辅助治疗的反应: 来自NeoSphere试验的探索性分析

2021-12-176
OA
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

HER2-Positive乳腺癌的综合分子和免疫表型以及对新辅助治疗的反应: 新探索性分析

2021-12-019
OA